tiprankstipranks
Advertisement
Advertisement

Viatris Launches Major Restructuring After Strong 2025 Results

Story Highlights
  • Viatris posted strong 2025 results, meeting guidance and returning over $1 billion to shareholders.
  • The company launched a major restructuring with up to 10% job cuts to unlock sizable cost savings and future growth.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Viatris Launches Major Restructuring After Strong 2025 Results

Claim 55% Off TipRanks

Viatris ( (VTRS) ) has issued an announcement.

On February 26, 2026, Viatris reported robust fourth-quarter 2025 revenues of $3.7 billion and full-year revenues of $14.3 billion, meeting or exceeding its 2025 financial guidance and returning more than $1 billion to shareholders, supported by strong cash generation and a balanced capital allocation approach. On the same date, the company completed its enterprise-wide strategic review, launching a restructuring plan that includes a global workforce reduction of up to about 10%, expected pre-tax charges of $700 million to $850 million and anticipated net cost savings of $600 million to $700 million over three years, positioning Viatris for operational efficiency gains and sustained revenue and earnings growth beginning in 2026.

The most recent analyst rating on (VTRS) stock is a Hold with a $16.00 price target. To see the full list of analyst forecasts on Viatris stock, see the VTRS Stock Forecast page.

Spark’s Take on VTRS Stock

According to Spark, TipRanks’ AI Analyst, VTRS is a Neutral.

Viatris’ overall stock score is driven by its strategic initiatives and positive technical momentum. However, financial challenges, particularly in profitability and valuation, weigh on the score. The company’s proactive steps in addressing operational issues and enhancing its market position are positive, but the financial performance remains a critical area for improvement.

To see Spark’s full report on VTRS stock, click here.

More about Viatris

Viatris Inc., listed on Nasdaq as VTRS, operates in the global pharmaceuticals industry, with a portfolio spanning branded medicines and generic drugs across developed and emerging markets, including Greater China and regions grouped as JANZ. The company focuses on generating stable cash flow from its broad base business while pursuing pipeline milestones and regulatory approvals to support long-term, sustainable growth.

Average Trading Volume: 9,023,974

Technical Sentiment Signal: Buy

Current Market Cap: $18.5B

See more data about VTRS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1